Vectus Biosystems
- Short interest
- <0.01%
- as of 10 Nov 2025
- Reported shorts
- 1.1K
- Shares on issue
- 53.333M
Vectus Biosystems (VBS) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $7.4KM (source: ASX (Markit))vs $18.8KM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- $1.6MM (source: ASX (Markit))vs −$1.8MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 14 Oct 2026
- EPS (diluted)
- $0.028T (source: Derived: trailing 12 months at year end)vs −$0.033 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- −60.4%FY
- EPS YoY
- n/aTTM
EPS: prior loss, now profit (growth is not meaningful against a loss).
- ASX (Markit)
- Derived: trailing 12 months at year end
Summary of Annual Report to shareholders, 18 Sep 2026
Vectus Biosystems reported a net profit of $1.56 million for FY2026, a turnaround from a restated loss of $1.86 million in FY2025. No dividend was declared. The company is focused on advancing its lead drug candidate VB0004 into a Phase Ib clinical trial for idiopathic pulmonary fibrosis.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 22 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- 20,977.8%
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- 3.2×
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Source: ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $7.4KM (source: ASX (Markit)) | $18.8KM (source: ASX (Markit)) | $76.9KM (source: ASX (Markit)) | $55.5KM (source: ASX (Markit)) |
| Operating income | n/a | n/a | −$3.5M | −$4.6M |
| EBITDA | n/a | n/a | −$2.3M | −$3.2M |
| EBIT | n/a | n/a | −$2.3M | −$3.2M |
| Interest expense | n/a | n/a | $8.7K | $205.5K |
| Pretax income | n/a | n/a | −$2.3M | −$3.4M |
| Tax | n/a | n/a | $0 | $0 |
| NPAT | $1.6MM (source: ASX (Markit)) | −$1.8MM (source: ASX (Markit)) | −$2.3M | −$3.4M |
| Net interest income | n/a | n/a | $68.2K | −$150.0K |
| EPS basic | $0.029T (source: Derived: trailing 12 months at year end) | −$0.033 | −$0.040 | −$0.072 |
| EPS diluted | $0.028T (source: Derived: trailing 12 months at year end) | −$0.033 | −$0.040 | −$0.072 |
| Shares | n/a | n/a | 53.2M | 53.2M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Annual Report to shareholdersAnnual Report18 Sep 2026via asx_announcements
- Preliminary Final ReportAnnual Results31 Aug 2026via asx_announcements
- Full Year Statutory AccountsFull Year Results31 Aug 2026via asx_announcements
- Quarterly Activities & Appendix 4C Cash Flow ReportsQuarterly Report28 Jul 2026via asx_announcements
- Quarterly Activities & Appendix 4C Cash Flow ReportsQuarterly Report30 Apr 2026via asx_announcements
- Half Year Report & Appendix 4DHalf Year Results26 Feb 2026via asx_announcements
- Quarterly Activities & Appendix 4C Cash Flow ReportsQuarterly Report30 Jan 2026via asx_announcements
- 2025 Annual ReportAnnual Report31 Dec 2025via crawler
- Quarterly Activities & Appendix 4C Cash Flow ReportsQuarterly Report30 Oct 2025via asx_announcements
- Annual Report to shareholdersAnnual Report29 Sep 2025via asx_announcements
Showing 10 of 32 reports